LOAC Announces Signing of Definitive Merger Agreement

Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement

4D pharma's Live Biotherapeutic Products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs

At the effective time of the merger, each of LOAC's ordinary shares issued and outstanding prior to the effective time of the merger will be automatically converted into the right to receive certain per share merger consideration, and each warrant to purchase LOAC's ordinary shares and right to receive LOAC's ordinary shares that is outstanding immediately prior to the effective time of the merger will be assumed by 4D pharma and automatically converted into a warrant to purchase ordinary shares of 4D pharma and a right to receive ordinary shares of 4D pharma, payable in 4D pharma ADSs, respectively.

prnewswire.com/news-releases/longevity-acquisition-corporation-announces-signing-of-definitive-merger-agreement-301157661.html